The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

22 Jan 2014 15:00

RNS Number : 2656Y
ValiRx PLC
22 January 2014
 

22 January 2014

ValiRx Plc

("ValiRx" or the "Company")

 

Grant of options

 

 

ValiRx Plc (AIM: VAL), the AIM listed life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that on 21 January 2014 it granted 133,000,000 options over ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to certain employees and directors of the Company, as set out in the table below.

 

 

Name of director

Number of shares held

% of issued share capital

Number of existing options

 

Number of new options granted

 

Total options now held

Options held as % of issued share capital

Satu Vainikka

22,324,198

0.76%

11,000,000

24,000,000

35,000,000

1.20%

George Morris

18,535,993

0.63%

6,750,000

22,000,000

28,750,000

0.98%

Gerry Desler

11,137,953

0.38%

6,400,000

22,000,000

28,400,000

0.97%

Kevin Alexander

6,421,940

0.22%

6,400,000

20,000,000

26,400,000

0.90%

Oliver de Giorgio-Miller

2,444,411

0.08%

3,000,000

20,000,000

23,000,000

0.79%

Seppo Makinen

Nil

Nil

Nil

8,000,000

8,000,000

0.27%

Total Directors

60,864,494

2.08%

33,550,000

116,000,000

149,550,000

5.12%

Others

Nil

Nil

6,100,000

17,000,000

23,100,000

0.79%

Total

60,864,495

2.08%

46,050,000

133,000,000

172,650,000

5.91%

 

 

The new options were granted under the Company's stock option plan and have an exercise price of 0.345p pence. The new options are exercisable from 21 January 2014 until 20 January 2024.

 

Following the grant of the new options, the total number of Ordinary Shares under option held by directors which could be issued is 149,550,000 Ordinary Shares, representing approximately 5.12 per cent. of the current issued share capital of the Company.

 

In addition, a further 17,000,000 options have been granted to others at an exercise price of 0.345 pence which are exercisable until 20 January 2024.

 

As at the date of this announcement the Company has a total of 179,050,000 shares under option.

 

The issued share capital of the Company comprises 2,921,043,420 ordinary shares of 0.1 pence each.

 

For more information, please contact:

 

Dr Satu Vainikka

ValiRx

 

Tel: +44 (0) 20 3008 4416

www.ValiRx.com

Liam Murray

Avi Robinson

Nominated Adviser

Cairn Financial Advisers

Tel: +44 (0) 20 7148 7900

David Hart

Mark Treharne

Broker

Daniel Stewart & Company

Tel: +44 (0) 20 7776 6550

Tarquin Edwards

Investor Relations

Peckwater PR

Tel: +44 (0) 7879 458 364

tarquin.edwards@peckwaterpr.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBXGDBBBDBGSD
Date   Source Headline
22nd Apr 20247:00 amRNSDirectorate Changes
21st Mar 20247:00 amRNSEvaluation Agreement with Imperial College London
19th Mar 20247:00 amRNSBoard Re-structuring and update on requisition
4th Mar 20245:47 pmRNSShareholder Requisition Notice
4th Mar 20247:00 amRNSProposed Appointment of Non-Executive Director
29th Feb 20242:00 pmRNSProposed Appointment of Non-Executive Director
13th Feb 20242:20 pmRNSFurther re Shareholder Requisition Notice
9th Feb 20245:06 pmRNSShareholder Requisition Notice
19th Jan 20247:00 amRNSChange of Broker
18th Jan 20247:00 amRNSDirectorate Change
4th Jan 20241:48 pmRNSResult of GM, Issue of Equity
19th Dec 20236:11 pmRNSResult of Retail Offer, Subscription
15th Dec 20237:00 amRNSPosting of Circular, Notice of GM and Ops Review
13th Dec 20234:56 pmRNSRetail Offer
13th Dec 20234:49 pmRNSConditional Fundraise, Notice of General Meeting
5th Dec 20237:00 amRNSAgreement to License VAL401 to Ambrose Healthcare
10th Nov 20237:00 amRNSEvaluation Agreement with StingRay Bio
6th Oct 202310:45 amRNSStatement re Share Price Movement
28th Sep 20237:00 amRNSOperational Review
24th Aug 20237:00 amRNSHalf-year Report
14th Aug 20237:00 amRNSCollaborative Services Agreement
19th Jul 20237:00 amRNSInaphaea BioLabs secures first external contract
28th Jun 20232:15 pmRNSResult of AGM
20th Jun 20237:00 amRNSVirtual AGM Access
19th Jun 20237:00 amRNSInaphaea BioLabs Operational Update
16th Jun 20237:00 amRNSConclusion of Hokkaido Evaluation Agreement
14th Jun 20237:00 amRNSAsset Purchase – Imagen Therapeutics
8th Jun 20237:00 amRNSUpdate on proposed sub-license of VAL201
7th Jun 20237:00 amRNSExpanded agreement with University of Barcelona
5th Jun 20237:00 amRNSFinal Results and Notice of AGM
26th May 20237:00 amRNSNotice of Results and Investor Webinar
26th Apr 20237:00 amRNSCollaborative Services Agreement
31st Mar 20237:00 amRNSQuarterly Operational Update
1st Mar 20237:02 amRNSInvestor Webinar
1st Mar 20237:00 amRNSIncorporation of Inaphaea BioLabs Limited
24th Feb 20234:40 pmRNSSecond Price Monitoring Extn
24th Feb 20234:35 pmRNSPrice Monitoring Extension
2nd Feb 202312:45 pmRNSResult of GM, Issue of Equity
31st Jan 20237:02 amRNSOperational Update
31st Jan 20237:00 amRNSHolding(s) in Company
17th Jan 20234:36 pmRNSBroker Offer Results
17th Jan 20239:22 amRNSPosting of Circular and Notice of General Meeting
13th Jan 20237:01 amRNSLaunch of Broker Offer
13th Jan 20237:00 amRNSIssue of Equity & Proposed Broker Offer
14th Dec 20225:01 pmRNSHolding(s) in Company
7th Dec 20221:06 pmRNSHolding(s) in Company
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
6th Dec 202212:00 pmRNSShareholder Communications and Investor Webinar
6th Dec 20227:00 amRNSQuarterly Operational and Strategy Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.